Minerva Neurosciences (NASDAQ: NERV) reported Q3 EPS of ($0.24), $0.03 worse than the analyst estimate of ($0.21).

Cash, cash equivalents and marketable securities as of September 30, 2016 were approximately $91.9 million, compared to $32.2 million as of December 31, 2015. As previously stated, Minerva expects that its cash, cash equivalents and marketable securities will be sufficient to fund its operations into 2018.

For earnings history and earnings-related data on Minerva Neurosciences (NERV) click here.